Current Report · Items 7.01, 9.01 · 8-K

Cartesian Therapeutics, Inc.

RNACNASDAQEQUITYCurrent

Regulation FD Disclosure

Filed Jun 9, 2026Accepted Jun 9, 2026, 7:16 AM EDTCIK 1453687Accession 0001140361-26-024556

Company context

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.

Current securities

RNACNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 9, 2026, Cartesian Therapeutics, Inc. (the “Company”) issued a press release announcing its entry into a strategic licensing agreement with WestGene Biopharma Co. (“WestGene”) to advance the development of novel in vivo chimeric antigen receptor T-cell (“CAR-T”) therapies in autoimmune diseases. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1, except as required by law.

Filed exhibits (1)

EX-99.1 (by filename) ef20075770_ex99-1.htm

EX-99.1 2 ef20075770_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans to advance multiple Cartesian-owned, internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding mRNA payload portfolio Clinical trial expected to initiate in 2H 2026 using mRNA payload from Descartes-08 combined with WestGene’s LNP platform in patients with MG; Clinical data expected in 1H 2027 FREDERICK, MD, June 9, 2026 (GLOBE NEWSWIRE) - Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced a strategic licensing agreement with WestGene Biopharma Co., Ltd. (“WestGene”) to advance the development of novel in vivo chimeric antigen receptor T-cell (CAR-T) therapies in autoimmune dis…

Open exhibit ↗

Get the free weekly BCS email.